Jazz Pharmaceuticals to Report 2015 First Quarter Financial Results on May 7, 2015

Audio webcast/conference call:
U.S. Dial-In Number:  +1 877 415 3179
International Dial-In Number: +1 857 244 7322
Passcode: 74301034

A replay of the conference call will be available through May 14, 2015 and accessible through one of the following telephone numbers, using the passcode below:

Replay U.S. Dial-In Number: +1 888 286 8010
Replay International Dial-In Number:  +1 617 801 6888
Passcode: 39160618

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is an international biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing meaningful products that address unmet medical needs.  The company has a diverse portfolio of products and/or product candidates with a focus in the areas of sleep and hematology/oncology.  In these areas, Jazz Pharmaceuticals markets Xyrem® (sodium oxybate) oral solution and Erwinaze® (asparaginase Erwinia chrysanthemi) in the U.S., and markets Erwinase® and Defitelio® (defibrotide) in Europe and other countries outside the U.S.  For more information, please visit www.jazzpharmaceuticals.com.